

Supplemental Table 5. Analysis of endogenous baseline Epo and LPFS in placebo treated patients by mRNA marker status.*

mRNA Marker/ Resection Stratum	Below Median† Marker Value or Negative			Above Median† Marker Value or Positive		
	Number of Patients		Log Rank P Value ‡	Number of Patients		Log Rank P Value ‡
	Low Serum Epo	High Serum Epo		Low Serum Epo	High Serum Epo	
<i>EpoR</i> mRNA						
All Patients	15	11	0.68	19	7	0.58
Residual Tumor	8	6	0.79	10	3	0.66
<i>Hsp70</i> mRNA§						
All Patients	20	10	0.53	20	9	0.23
Residual Tumor	12	3	0.54	9	6	0.79
<i>Jak2</i> mRNA						
All Patients	16	12	0.69	21	7	0.66
Residual Tumor	11	4	0.62	9	5	0.84

* Stratification was above versus below/equal to the median for the mRNA markers.

† The median was calculated separately for all patients and within each resection stratum.

‡ The p value is based on the log rank test to compare differences in Kaplan Meier distributions in patients with high versus low baseline serum Epo levels. The p value is two-sided.

§ *Hsp70* mRNA represents the cumulative expression of all 8 family members.